Aerin Medical – a high-growth medical device company focused on expanding access to meaningful relief for millions of patients suffering from chronic ENT conditions – announced the completion of two significant financial transactions.
These deals position the company to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin’s major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital.
KEY QUOTES:
“This additional funding significantly strengthens our financial position, supporting continued commercial expansion, along with investments in significant R&D and leading clinical evidence-generation that have been signatures of Aerin’s progress. The confidence demonstrated by our investors reflects the momentum we’ve built in bringing meaningful innovations to otolaryngologists and their patients.”
– Matt Brokaw, CEO of Aerin Medical
“We are proud to support Aerin and the significant advancements they continue to make in ENT care. This is an exciting time for Aerin as they continue to deepen their penetration in the market for large unmet medical needs in nasal obstruction and chronic rhinitis. Our focus will be on ensuring access to these critical technologies for all patients who would benefit.”
– Karen Long, Sr. Managing Director at KCK Group and Chairman of Aerin Medical Board of Directors
“We are excited to provide financing to Aerin as they continue to expand their footprint in ENT. The strength of Aerin’s management team and their strong track record of well-designed, well-studied solutions is a testament to their dedication and expertise. We look forward to supporting them in their next phase of growth.”
– Kris Talgo, Principal in the at Ares Credit Group
